

Subject: Under embargo: Doctors discover breakthrough treatment of congenital hyperinsulinism in children

Hi XXX,

Doctors at Qatar Foundation's Sidra Medicine, a renowned hospital dedicated to the care of women and children in Doha, Qatar, discovered a breakthrough method for treating children suffering from congenital hyperinsulinism (CHI) - a genetic disorder in which the insulin cells of the pancreas, called beta cells, secrete too much insulin. CHI causes low plasma sugar (hypoglycemia), or low blood sugar, and if left untreated, can lead to brain damage or death.

[Dr. Khalid Hussein \[https://www.sidra.org/doctors-and-nurse-practitioners/khalid-hussain\]](https://www.sidra.org/doctors-and-nurse-practitioners/khalid-hussain) , Division Chief of Pediatric Endocrinology at Sidra Medicine, and his team trialed *Alpelisib* - a medication that is typically used to treat breast cancer patients - on a four-month-old baby with severe CHI who was not responding to conventional medical therapies, successfully counteracting her low blood sugar levels and avoiding a pancreatectomy. ***This treatment marks the first time in medical history that Alpelisib has been repurposed to treat severe low blood sugar levels in an infant, highlighting an innovative new therapy that will benefit thousands of children around the world.***

The results of the trial will be published as a case study in New England Journal of Medicine, which is **embargoed until Wednesday, January 24, at 5:00pm ET.**

Further details are available upon acceptance of the embargo; please confirm if you would like to see additional materials.

I can also connect you with Dr. Khalid Hussein virtually or via email to discuss:

- What this groundbreaking trial means for the treatment of CHI in children across the globe
- How Dr. Khalid Hussein and his team at Sidra Medicine work to find innovative treatment solutions when conventional methods fail to control and treat widespread health disorders
- How Dr. Khalid Hussein and his team will use this trial to inform future patient use cases

Best,
XXX

This material is distributed by RF|Binder Partners Inc. on behalf of the Qatar Foundation. Additional information is available at the Department of Justice, Washington, D.C.